glp-1 receptor agonists cardiovascular benefits in the Rehabilitation of Patients with Heart Failure: Mechanisms, Clinical Evidence, and Future Perspectives Bridging the gap between GLP1-receptor

It is even possible that the insulin-stimulating, glucagon-suppressing effects of the peptide or a more active synthetic analogue may be useful in the treatment of non-insulin-dependent diabetes, in which both impaired insulin release in response to glucose and persistent hyperglucagonemia are thought to be key pathophysiological abnormalities' (Kreymann, Ghattei, Williams, Bloom)

Since 2005, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been used as key therapeutic agents for T2DM [4, 5, 6]

P = 0.004) according to the results of the meta-analysis

One innovative therapy we offer is the Ozempic shot, a GLP-1 receptor agonist originally developed to manage type 2 diabetes and now widely recognized for its remarkable effectiveness in promoting weight loss

65% of patients achieved more than 10% weight loss compared to 0% placebo

Although their long-term side effects arent fully understood, studies to-date show they are safe and effective for use, and that their health benefits generally outweigh their side effects for most people